3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      TAK-375 Takeda.

      Current opinion in investigational drugs (London, England : 2000)
      Animals, Clinical Trials as Topic, Humans, Indenes, adverse effects, pharmacokinetics, therapeutic use, Receptor, Melatonin, MT1, agonists, Sleep Disorders, drug therapy, metabolism

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          TAK-375 (Ramelteon), a melatonin ML1/MT1 receptor agonist for the potential treatment of primary insomnia, is being developed by Takeda. Takeda submitted an NDA to the FDA for TAK-375 in September 2004.

          Related collections

          Author and article information

          Comments

          Comment on this article